Noticias de ATOS_US

Noticias del mercado

Últimas noticias sobre ATOS_US — 39 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.

Ticker: ATOS_US ✕ 39 resultados
24/04/2026 ATOS_US — Traders Union
Atossa Therapeutics joins industry leaders at LSINW2026 to advance cell therapy innovation momentum
17/04/2026 ATOS_US — ChartMill ES ← EN
Precio, cotización y gráfico de acciones de ATOS | ATOSSA TERAPÉUTICA INC (NASDAQ:ATOS)
17/04/2026 ATOS_US — ChartMill
ATOS Ownership | ATOSSA THERAPEUTICS INC (NASDAQ:ATOS)
16/04/2026 ATOS_US — TipRanks
Atossa Therapeutics Resolves Endoxifen Patent Disputes, Clarifies Rights
16/04/2026 ATOS_US — Investing.com ES ← EN
Atossa Therapeutics llega a un acuerdo en la disputa sobre la patente del endoxifeno Por Investing.com
16/04/2026 ATOS_US — Investing.com
Atossa Therapeutics reaches settlement in Endoxifen patent dispute By Investing.com
16/04/2026 ATOS_US — Investing.com
Atossa Therapeutics reaches settlement in Endoxifen patent dispute By Investing.com
16/04/2026 ATOS_US — Investing.com
Atossa Therapeutics reaches settlement in Endoxifen patent dispute
16/04/2026 ATOS_US — Investing.com
Atossa Therapeutics reaches settlement in Endoxifen patent dispute By Investing.com
16/04/2026 ATOS_US — Stock Titan
Atossa Therapeutics (NASDAQ: ATOS) settles key Endoxifen patent fight
14/04/2026 ATOS_US — Traders Union
Atossa Therapeutics advances endoxifen as new option for DMD management
13/04/2026 ATOS_US — MSN ES ← EN
El precio objetivo de Atossa Therapeutics (ATOS) disminuyó un 31,37% a 44,62
10/04/2026 ATOS_US — MSN
Atossa Therapeutics (ATOS) price target decreased by 31.37% to 44.62
10/04/2026 ATOS_US — GuruFocus
ATOS: Ascendiant Capital Lowers Price Target Despite Maintaining 'Buy' Rating | ATOS Stock News
03/04/2026 ATOS_US — laocai.gov.vn ES ← EN
Ganancias de ATOS Q4 2025: Atossa Therapeutics Inc pierde EPS sin ingresos
03/04/2026 ATOS_US — tayninh.gov.vn
ATOS Q4 2025 Earnings: Atossa Therapeutics Inc misses EPS with no revenue
31/03/2026 ATOS_US — Stock Titan
Atossa (NASDAQ: ATOS) CEO Steven Quay granted 65,000 RSUs after reverse split
30/03/2026 ATOS_US — Stock Titan
[DEF 14A] ATOSSA THERAPEUTICS, INC. Definitive Proxy Statement
30/03/2026 ATOS_US — Stock Titan
Atossa Therapeutics (ATOS) CFO receives 63,000 RSUs over 3 years
26/03/2026 ATOS_US — Minichart
Atossa Therapeutics Reports 2025 Financial Results and Advances (Z)-Endoxifen in Rare Diseases and Oncology

Página 1 de 2

keyboard_arrow_up